Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily pract...

Full description

Bibliographic Details
Main Authors: Juul M.P.A. van den Reek, Lieke J. van Vugt, Martijn B.A. van Doorn, Gayle E. van der Kraaij, Wim J.A. de Kort, Georges P.H. Lucker, Barbara Horvath, M. David Njoo, H. Jorn Bovenschen, Paul M. Ossenkoppele, Marjolein S. De Bruin-Weller, Marjan de Groot, Roland Mommers, Ruud L.M.A. Prevoo, Peter C.M. van de Kerkhof, Phyllis I. Spuls, Wietske Kievit, Elke M.G.J. de Jong
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2018-04-01
Series:Acta Dermato-Venereologica
Subjects:
psoriasis
secukinumab
biologics
drugsurvival
effectiveness.
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2900

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2900

Similar Items